Streetbeat News

QSI

Quantum-Si incorporated

Industry

Biotechnology

Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.

Open

1.35

Mkt cap

84M

Volume

16M

High

1.36

P/E Ratio

-2.02

52-wk high

2.43

Low

1.18

Div yield

N/A

52-wk low

0.61

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Quantum-Si (NASDAQ:QSI) with a maintained price target of $4.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 11:36 am

Quantum-Si forecasts its FY24 revenue to be between $3.7M and $4.2M, which is around the analyst estimate of $4.076M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 10:07 pm

Quantum-Si reported Q1 2024 earnings with a smaller loss per share of $(0.14) compared to the expected $(0.19), and sales of $457,000, surpassing the $426,500 estimate. This represents a significant improvement over the previous year's performance.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:11 pm

U.S. stocks were lower on Monday, with the Dow Jones index falling over 150 points. EQT Corporation's shares dropped 8.4% after announcing a merger with Equitrans Midstream. Other notable declines include Ventyx Biosciences, MoneyLion Inc., Genie Energy Ltd., and several others, each falling due to various company-specific news such as clinical data reports, quarterly results, and strategic updates.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 2:37 pm

In Thursday's intraday session, several health care stocks experienced significant movements. Notably, Psyence Biomedical, ZyVersa Therapeutics, Creative Medical Tech, HeartBeam, Ocean Biomedical, and Quantum-Si saw their stock prices increase by over 20%. Conversely, Avid Bioservices, Aptorum Gr, Nexalin Technology, BeyondSpring, PepGen, and Viking Therapeutics faced declines, with some dropping by over 30%. These movements reflect notable volatility within the health care sector.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 5:31 pm

Insiders at Earth Science Tech, Standard BioTools, and Quantum-Si have recently made significant stock purchases. Earth Science Tech announced a $5 million stock repurchase program, Standard BioTools reported better-than-expected Q4 revenue, and Quantum-Si posted upbeat quarterly results. These insider transactions indicate confidence in the companies' prospects.

Portfolio Pulse from Avi Kapoor

March 07, 2024 | 11:33 am

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Quantum-Si (NASDAQ:QSI) and raises the price target from $3 to $4.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 12:31 pm

Quantum-SI projects its FY24 revenue to be between $3.7M and $4.2M, surpassing the estimated $3.339M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:11 pm

Quantum-Si (NASDAQ:QSI) reported Q4 earnings, beating estimates with an EPS of $-0.16 against an expected $-0.18. Revenue increased by $400 thousand from the previous year. Following last quarter's earnings beat, the share price increased by 7% the next day.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 9:40 pm

Quantum-Si reported Q4 2023 earnings with a GAAP EPS of $(0.160), surpassing the $(0.200) estimate. Sales reached $400,000, exceeding the $299,500 forecast.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.